Healthcare (603313) ZHESHANG SECURITIES·2025-05-18 14:20Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is showing signs of recovery in North America, with a notable improvement in profitability [1][2] - The company is actively upgrading its store formats and expanding its product categories [3] - The company is implementing cost reduction and efficiency improvement measures, which are yielding positive results [5] - The revenue forecast for 2025-2027 indicates a steady growth trajectory, with expected revenues of 96.71 billion, 111.70 billion, and 129.03 billion respectively [6][11] Revenue Overview - In 2024, the company achieved a revenue of 84.49 billion (up 5.94%), with a net profit attributable to shareholders of -1.51 billion (down 242.04%) [1] - For Q4 2024, the company reported a revenue of 23.24 billion (up 2.80%) and a net profit of 0.02 billion (up 124.68%) [1] - In Q1 2025, the company achieved a revenue of 20.43 billion (up 12.31%) and a net profit of 0.59 billion (up 196.22%) [1] Regional Performance - In 2024, North America generated a revenue of 43.34 billion (down 1.1%), while Europe saw a revenue increase of 20.35% to 19.55 billion [2] - In Q1 2025, North America reported a revenue of 10.19 billion (up 10.04%), and Europe reported 5.13 billion (up 17.36%) [2] Product and Channel Breakdown - In 2024, the company’s mattress segment generated 44.15 billion (up 10.95%), while the pillow segment saw a slight decline of 0.25% [3] - The company’s online sales increased significantly by 37.61% in 2024, reaching 17.97 billion [4] Cost Management - The gross margin for 2024 was 36.85% (down 1.5 percentage points), but improved to 39.37% in Q1 2025 (up 0.84 percentage points) [5] - The company’s management and R&D expense ratio decreased to 7.56% in Q1 2025 [5] Profitability Forecast - The company is expected to turn profitable in 2025 with a net profit of 3.01 billion, followed by 3.73 billion in 2026 and 4.79 billion in 2027 [6][11]